Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.23.B10 - Rous sarcoma virus retropepsin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
A cell-penetrating helical peptide as a potential HIV-1 inhibitor.
Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
AIDS-related lipodystrophy/insulin resistance syndrome.
Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/lipodystrophy syndrome?
Reversal of HIV drug resistance and novel strategies to curb HIV infection: the viral infectivity factor Vif as a target and tool of therapy.
The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19).
Adenocarcinoma of Lung
Jaagsiekte sheep retrovirus is not detected in human lung adenocarcinomas expressing antigens related to the Gag polyprotein of betaretroviruses.
Adenomatous Polyposis Coli
The tumour suppressor APC promotes HIV-1 assembly via interaction with Gag precursor protein.
Adenoviridae Infections
Detection and Quantification of Label-Free Infectious Adenovirus Using a Switch-On Cell-Based Fluorescent Biosensor.
Inhibition of adenovirus infection and adenain by green tea catechins.
Alzheimer Disease
Expression of the plant viral protease NIa in the brain of a mouse model of Alzheimer's disease mitigates A? pathology and improves cognitive function.
Anemia
Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly.
Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication.
Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection.
Anemia, Hemolytic
Sequences responsible for the distinctive hemolytic potentials of Friend and Moloney murine leukemia viruses are dispersed but confined to the psi-gag-PR region.
Angina Pectoris
The chemistry and pharmacology of alkaloids and allied nitrogen compounds from Artemisia species: A review.
Avian Leukosis
Proteolytic cleavage at the Gag-Pol junction in avian leukosis virus: differences in vitro and in vivo.
trans-acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase.
Carcinoma
Immunohistochemical determination of the P15 protein expression in cutaneous squamous cell carcinoma.
Carcinoma, Hepatocellular
Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells.
Carcinoma, Squamous Cell
Immunohistochemical determination of the P15 protein expression in cutaneous squamous cell carcinoma.
Cardiomyopathies
Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy.
Coronavirus Infections
Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
COVID-19
Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.
Carvacrol, a Plant Metabolite Targeting Viral Protease (Mpro) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19.
Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19.
Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 through a Molecular Docking Study.
Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
In silico analysis of phytochemicals as potential inhibitors of proteases involved in SARS-CoV-2 infection.
Molecular modeling study of tectoquinone and acteoside from Tectona grandis linn: a new SARS-CoV-2 main protease inhibitor against COVID-19.
Role of Iron Chelation and Protease Inhibition of Natural Products on COVID-19 Infection.
Should COVID-19 be branded to viral thrombotic fever?
The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19).
The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Coxsackievirus Infections
Viral protease cleavage of inhibitor of kappaBalpha triggers host cell apoptosis.
Dengue
Activation of dengue protease autocleavage at the NS2B-NS3 junction by recombinant NS3 and GST-NS2B fusion proteins.
Cleavage of the dengue virus polyprotein at the NS3/NS4A and NS4B/NS5 junctions is mediated by viral protease NS2B-NS3, whereas NS4A/NS4B may be processed by a cellular protease.
Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.
Dengue viral protease interaction with NF-?B inhibitor ?/? results in endothelial cell apoptosis and hemorrhage development.
Dengue virus protease activity modulated by dynamics of protease cofactor.
Development and utility of an in vitro, fluorescence-based assay for the discovery of novel compounds against dengue 2 viral protease.
Structural insights into a multifunctional inhibitor, 'AMTIN' from tubers of Alocasia macrorrhizos and its possible role in dengue protease (NS2B-NS3) inhibition.
Synthesis and biological evaluation of ?-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture.
Diabetes Mellitus
Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
Encephalitis
Substrate-based peptidomimetic inhibitors of the Murray Valley encephalitis virus NS2B/NS3 serine protease: A P1-P4 SAR study.
Encephalitis, Japanese
Processing of Japanese encephalitis virus non-structural proteins: NS2B-NS3 complex and heterologous proteases.
Enzootic Bovine Leukosis
A new form of particulate single and multiple immunogen delivery system based on recombinant bluetongue virus-derived tubules.
Bovine leukemia virus Gag particle assembly in insect cells: formation of chimeric particles by domain-switched leukemia/lentivirus Gag polyprotein.
Involvement of the matrix and nucleocapsid domains of the bovine leukemia virus Gag polyprotein precursor in viral RNA packaging.
Equine Infectious Anemia
Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly.
Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication.
Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection.
Foot-and-Mouth Disease
Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12.
Plant molecular farming of virus-like nanoparticles as vaccines and reagents.
Glioblastoma
Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme.
Hand, Foot and Mouth Disease
Expression, purification and characterization of enterovirus-71 virus-like particles.
Hepatitis A
Comparative evaluation of new TaqMan real-time assays for the detection of hepatitis A virus.
Hepatitis E virus persists in the presence of a type III interferon response.
Hepatitis B
A new form of particulate single and multiple immunogen delivery system based on recombinant bluetongue virus-derived tubules.
Plant molecular farming of virus-like nanoparticles as vaccines and reagents.
Hepatitis C
A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
A high-throughput radiometric assay for hepatitis C virus NS3 protease.
Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation.
Antiviral innate immunity pathways.
Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.
Curing a viral infection by targeting the host: the example of cyclophilin inhibitors.
Global Origin and Transmission of Hepatitis C Virus Nonstructural Protein 3 Q80K Polymorphism.
HCV protease inhibitory, cytotoxic and apoptosis-inducing effects of oleanolic acid derivatives.
Hepatitis C virus/human interactome identifies SMURF2 and the viral protease as critical elements for the control of TGF-? signaling.
Hepatitis E virus persists in the presence of a type III interferon response.
High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design.
Improving Viral Protease Inhibitors to Counter Drug Resistance.
Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp.
Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells.
Ligand screening using enzymatic assays.
Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease.
Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
Overview of interferon therapy for chronic hepatitis C.
Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese.
Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3.
Recombinant adeno-associated virus expressing a modified transcription factor triggered by the hepatitis C viral protease NS3/4a.
Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest?
SCREENING OF PROTEASE INHIBITORS RESISTANCE MUTATIONS IN HEPATITIS C VIRUS ISOLATES INFECTING ROMANIAN PATIENTS UNEXPOSED TO TRIPLE THERAPY.
Telaprevir to boceprevir switch highlights lack of cross-reactivity.
Therapy of hepatitis C: other options.
Treatment of chronic hepatitis C.
Validating Enterovirus D68-2Apro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2Apro Inhibitor.
Hepatitis C, Chronic
Overview of interferon therapy for chronic hepatitis C.
Therapy of hepatitis C: other options.
[The molecular biology of hepatitis C virus.]
Herpes Simplex
The putative herpes simplex virus 1 chaperone protein UL32 modulates disulfide bond formation during infection.
HIV Infections
Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers.
Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2.
Mechanism of indinavir-induced hyperbilirubinemia.
Proteolytic events of HIV-1 replication as targets for therapeutic intervention.
Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Hyperlipidemias
Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?
Infections
A catalogue of putative HIV-1 protease host cell substrates.
Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
Antiviral treatment of hepatitis C: present status and future prospects.
Characterization of human immunodeficiency virus type 1 (HIV-1) containing mutations in the nucleocapsid protein at a putative HIV-1 protease cleavage site.
Citrus Psorosis Virus Movement Protein Contains an Aspartic Protease Required for Autocleavage and the Formation of Tubule-Like Structures at Plasmodesmata.
Cleavage of sequestosome 1/p62 by an enteroviral protease results in disrupted selective autophagy and impaired NFKB signaling.
Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.
Contribution of PDZD8 to Stabilization of the Human Immunodeficiency Virus Type 1 Capsid.
Coxsackievirus Counters the Host Innate Immune Response by Blocking Type III Interferon Expression.
Cytoplasmic translocation, aggregation, and cleavage of TDP-43 by enteroviral proteases modulate viral pathogenesis.
Cytoskeletal association of an aphthovirus-induced polypeptide derived from the P3ABC region of the viral polyprotein.
Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function.
Foot-and-Mouth Disease Virus Counteracts on Internal Ribosome Entry Site Suppression by G3BP1 and Inhibits G3BP1-Mediated Stress Granule Assembly via Post-Translational Mechanisms.
Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!
HIV type 1 integrase inhibitors: from basic research to clinical implications.
HIV-1 matrix protein p17 resides in cell nuclei in association with genomic RNA.
HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction.
Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis.
Intracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses.
Murine leukemia viruses: objects and organisms.
N-Naphthoyl-substituted indole thio-barbituric acid analogs inhibit the helicase activity of the hepatitis C virus NS3.
New stimulation ligand of the adenovirus 2 protease.
Nidovirus papain-like proteases: Multifunctional enzymes with protease, deubiquitinating and deISGylating activities.
Nuclear entry of poliovirus protease-polymerase precursor 3CD: implications for host cell transcription shut-off.
Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts.
Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese.
Protease-dependent uncoating of a complex retrovirus.
Recombinant adeno-associated virus expressing a modified transcription factor triggered by the hepatitis C viral protease NS3/4a.
SCREENING OF PROTEASE INHIBITORS RESISTANCE MUTATIONS IN HEPATITIS C VIRUS ISOLATES INFECTING ROMANIAN PATIENTS UNEXPOSED TO TRIPLE THERAPY.
Should COVID-19 be branded to viral thrombotic fever?
Structural and molecular determinants of HIV-1 Gag binding to the plasma membrane.
Structure of the NS2B-NS3 protease from Zika virus after self-cleavage.
TAR DNA-Binding Protein 43 is Cleaved by the Protease 3C of Enterovirus A71.
The flavivirus protease as a target for drug discovery.
The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
The mammalian host protein DAP5 facilitates the initial round of translation of Coxsackievirus B3 RNA.
Transcriptome profiling reveals infection strategy of an insect maculavirus.
Virus maturation as a new HIV-1 therapeutic target.
[New therapies for hepatitis C]
Influenza, Human
Analysis of bovine leukemia virus gag membrane targeting and late domain function.
Plant molecular farming of virus-like nanoparticles as vaccines and reagents.
The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19).
Insulin Resistance
Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?
Leukemia
An internal ribosomal entry mechanism promotes translation of murine leukemia virus gag polyprotein precursors.
Avian sarcoma leukemia virus protease linked to the adjacent Gag polyprotein is enzymatically active.
Construction and characterization of Moloney murine leukemia virus mutants unable to synthesize glycosylated gag polyprotein.
Cooperative effect of gag proteins p12 and capsid during early events of murine leukemia virus replication.
Genetic assay for multimerization of retroviral gag polyproteins.
Genetic control of natural immunity to ecotropic mouse leukemia viruses: immune response genes.
HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation.
Immune response of the mouse to the major core protein (p30) of ecotropic leukemia viruses.
Localization of actin in Moloney murine leukemia virus by immunoelectron microscopy.
Murine leukemia virus glycosylated Gag (gPr80gag) facilitates interferon-sensitive virus release through lipid rafts.
Mutation in the glycosylated gag protein of murine leukemia virus results in reduced in vivo infectivity and a novel defect in viral budding or release.
Mutations at the capsid-nucleocapsid cleavage site of gag polyprotein of Moloney murine leukemia virus abolish virus infectivity.
Mutations in the cytoplasmic tail of murine leukemia virus envelope protein suppress fusion inhibition by R peptide.
Novel fatty acyl substrates for myristoyl-CoA:protein N-myristoyl-transferase.
Promyelocytic Leukemia Restricts Enterovirus 71 Replication by Inhibiting Autophagy.
Properties of retroviral protease responsible for gag precursor cleavage.
Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid.
The Cellular Protein La Functions in Enhancement of Virus Release through Lipid Rafts Facilitated by Murine Leukemia Virus Glycosylated Gag.
The effect of cerulenin on the synthesis of the precursor gag polyprotein in defective murine leukemia and sarcoma virus producing cell lines.
The nucleocapsid domain is responsible for the ability of spleen necrosis virus (SNV) Gag polyprotein to package both SNV and murine leukemia virus RNA.
Viral interactions with the host-cell cytoskeleton: the role of retroviral proteases.
Leukemia, Feline
Mutation in the glycosylated gag protein of murine leukemia virus results in reduced in vivo infectivity and a novel defect in viral budding or release.
Leukemia, T-Cell
PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101 [corrected].
Lipodystrophy
Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
Mitochondria and HIV infection: the first decade.
Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?
Liver Diseases
HCV protease inhibitory, cytotoxic and apoptosis-inducing effects of oleanolic acid derivatives.
Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
Lymphatic Metastasis
[Expression of p15 protein in poorly differentiated nasopharyngeal carcinoma]
Mouth Diseases
Expression, purification and characterization of enterovirus-71 virus-like particles.
Plant molecular farming of virus-like nanoparticles as vaccines and reagents.
Murine Acquired Immunodeficiency Syndrome
CTL responses to the gag polyprotein encoded by the murine AIDS defective retrovirus are strain dependent.
STAT6-deficient mice exhibit normal induction of murine AIDS and expression of immunoglobulin E following infection with LP-BM5 murine leukemia viruses.
Nasopharyngeal Carcinoma
[Expression of p15 protein in poorly differentiated nasopharyngeal carcinoma]
Neoplasm Metastasis
[Expression of p15 protein in poorly differentiated nasopharyngeal carcinoma]
Neoplasms
Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.
Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme.
Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2.
Cyclin-Dependent Kinase Inhibitor 2b Controls Fibrosis and Functional Changes in Ischemia-Induced Heart Failure via the BMI1-p15-Rb Signalling Pathway.
Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas.
In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas.
Localization of self-interacting domains within betaretrovirus Gag polyproteins.
Membrane properties of the gag gene-coded p15 protein of mouse type-C RNA tumor viruses.
Poliovirus 3C protease-mediated degradation of transcriptional activator p53 requires a cellular activity.
Premature processing of mouse mammary tumor virus Gag polyprotein impairs intracellular capsid assembly.
Seneca Valley Virus 3C Protease Induces Pyroptosis by Directly Cleaving Porcine Gasdermin D.
The tumour suppressor APC promotes HIV-1 assembly via interaction with Gag precursor protein.
Pancreatitis, Acute Necrotizing
Active residues and viral substrate cleavage sites of the protease of the birnavirus infectious pancreatic necrosis virus.
Peritonitis
In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus.
Pulmonary Adenomatosis, Ovine
Jaagsiekte sheep retrovirus is not detected in human lung adenocarcinomas expressing antigens related to the Gag polyprotein of betaretroviruses.
Rubella
A cysteine-rich metal-binding domain from rubella virus non-structural protein is essential for viral protease activity and virus replication.
Sarcoma
Identification of a new viral protein containing CAp30 and NCp10 sequences in murine and feline leukemia retroviruses.
Properties of retroviral protease responsible for gag precursor cleavage.
The effect of cerulenin on the synthesis of the precursor gag polyprotein in defective murine leukemia and sarcoma virus producing cell lines.
Sarcoma, Avian
1H, 15N and 13C assignments of a monomeric N-terminal deletion mutant of the Rous sarcoma virus protease.
Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation.
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly.
Avian sarcoma leukemia virus protease linked to the adjacent Gag polyprotein is enzymatically active.
Cleavage of four avian sarcoma virus polyproteins with virion protease p15 removes gag sequences and yields large fragments that function as tyrosine phosphoacceptors in vitro.
Cleavage of the X-Pro peptide bond by pepsin is specific for the trans isomer.
Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.
Deletion of a Cys-His motif from the Alpharetrovirus nucleocapsid domain reveals late domain mutant-like budding defects.
Detailed mapping of the nuclear export signal in the Rous sarcoma virus Gag protein.
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain.
Importance of basic residues in binding of rous sarcoma virus nucleocapsid to the RNA packaging signal.
Importance of the N terminus of rous sarcoma virus protease for structure and enzymatic function.
Incorporation of chimeric gag protein into retroviral particles.
Modeling of structure of human immunodeficiency virus-1 protease with substrate based on crystal structure of Rous sarcoma virus protease.
Molecular mechanics calculations on Rous sarcoma virus protease with peptide substrates.
Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases.
Mutations affecting cleavage at the p10-capsid protease cleavage site block Rous sarcoma virus replication.
Mutations that alter the activity of the Rous sarcoma virus protease.
NMR Relaxation Studies of an RNA-Binding Segment of the Rous Sarcoma Virus Gag Polyprotein in Free and Bound States: A Model for Autoinhibition of Assembly.
Nuclear entry and CRM1-dependent nuclear export of the Rous sarcoma virus Gag polyprotein.
Overlapping roles of the Rous sarcoma virus Gag p10 domain in nuclear export and virion core morphology.
Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Possible role of some groups in the structure and function of HIV-1 protease as revealed by molecular modeling studies.
Production of Rous sarcoma virus-like particles displaying human transmembrane protein in silkworm larvae and its application to ligand-receptor binding assay.
Programming the Rous sarcoma virus protease to cleave new substrate sequences.
Proteases from human immunodeficiency virus and avian myeloblastosis virus show distinct specificities in hydrolysis of multidomain protein substrates.
Proteolytic activity of purified avian sarcoma and leukemia virus NC-PR protein expressed in Escherichia coli.
Requirement of N- and C-terminal regions for enzymatic activity of human T-cell leukemia virus type I protease.
RNA-Binding Domains of Heterologous Viral Proteins Substituted for Basic Residues in the RSV Gag NC Domain Restore Specific Packaging of Genomic RNA.
Role of the gag polyprotein precursor in packaging and maturation of Rous sarcoma virus genomic RNA.
Site-directed mutagenesis of the P2 region of the Rous sarcoma virus gag gene: effects on Gag polyprotein processing.
Structural basis for targeting avian sarcoma virus Gag polyprotein to the plasma membrane for virus assembly.
Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2-A resolution.
Structure-based design of symmetric inhibitors of HIV-1 protease.
Starvation
Glutamine starvation of murine leukaemia virus-infected cells inhibits the readthrough of the gag-pol genes and proteolytic processing of the gag polyprotein.
Vaccinia
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.
Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation.
Processing of Japanese encephalitis virus non-structural proteins: NS2B-NS3 complex and heterologous proteases.
Processing of the intracellular form of the west Nile virus capsid protein by the viral NS2B-NS3 protease: an in vitro study.
Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen.
Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.
Viremia
Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo.
Virus Diseases
Cytoplasmic viral RNA-dependent RNA polymerase disrupts the intracellular splicing machinery by entering the nucleus and interfering with Prp8.
Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease.
Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
Inhibitor of NF kappa B alpha is a host sensor of coxsackievirus infection.
New stimulation ligand of the adenovirus 2 protease.
Regulated Cleavages at the West Nile Virus NS4A-2K-NS4B Junctions Play a Major Role in Rearranging Cytoplasmic Membranes and Golgi Trafficking of the NS4A Protein.
Stimulation of the Internal Ribosome Entry Site (IRES)-Dependent Translation of Enterovirus 71 by DDX3X RNA Helicase and Viral 2A and 3C Proteases.
Substrate-based peptidomimetic inhibitors of the Murray Valley encephalitis virus NS2B/NS3 serine protease: A P1-P4 SAR study.
Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo.
The C-terminal amyloidogenic peptide contributes to self-assembly of Avibirnavirus viral protease.
Visna
Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells.
West Nile Fever
Synthesis and biological evaluation of ?-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture.
Zika Virus Infection
Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo.